Dynamic Technology Lab Private Ltd Buys Shares of 29,772 Hologic, Inc. (NASDAQ:HOLX)

Dynamic Technology Lab Private Ltd purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 29,772 shares of the medical equipment provider's stock, valued at approximately $2,425,000.

A number of other large investors also recently bought and sold shares of HOLX. Innealta Capital LLC purchased a new stake in Hologic during the second quarter worth $25,000. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic during the 3rd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the 1st quarter valued at about $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the 2nd quarter valued at about $37,000. Finally, First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of Hologic stock traded up $0.67 on Monday, hitting $79.64. 512,469 shares of the company were exchanged, compared to its average volume of 1,583,054. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.50 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The company has a 50-day moving average price of $80.44 and a 200 day moving average price of $78.35.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. During the same period in the prior year, the business earned $0.89 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the company. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Raymond James upped their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Finally, Stephens reissued an "overweight" rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.